Page last updated: 2024-08-21

pyrazines and Bone Cancer

pyrazines has been researched along with Bone Cancer in 28 studies

Research

Studies (28)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (28.57)	29.6817
2010's	17 (60.71)	24.3611
2020's	3 (10.71)	2.80

Authors

Authors	Studies
Chen, Z; Chramiec, A; Halligan, SP; House, JS; Liu, Y; Rusyn, I; Sakolish, C; Vunjak-Novakovic, G	1
Gondhowiardjo, S; Gu, W; Kakoti, S; Kato, R; Ohno, T; Oike, T; Permata, TBM; Sato, H; Sato, I; Shibata, A; Suzuki, K; Tsushima, Y; Uchihara, Y; Yamauchi, M; Yasuhara, T; Yoshimatsu, Y	1
Demir, B; Demir, E; Sütcüoğlu, O; Ünsal, O; Yazıcı, O	1
Davaadelger, B; Duan, L; Gitelis, S; Maki, CG; Perez, RE; Zhou, Y	1
Briaire-de Bruijn, IH; Cleton-Jansen, AM; Hassan, AB; Hogendoorn, PC; Kuijjer, ML; Meza-Zepeda, LA; Myklebost, O; Peterse, EF; Serra, M; van den Akker, BE	1
Fu, Q; Wang, Y; Zhao, W	1
Ambati, SR; Chiosis, G; Kosugi, K; Lopes, EC; Meyers, PA; Mony, U; Moore, MA; Moreira, AL; Shah, SK; Taldone, T; Zehir, A	1
Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K	1
Baron, R; Basto, P; Bertrand, N; Farokhzad, OC; Ghobrial, IM; Glavey, S; Kamaly, N; Liu, J; Lu, ZN; Manier, S; Memarzadeh, M; Mishima, Y; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Sacco, A; Seevaratnam, D; Shi, J; Swami, A; Wu, J; Zhang, S; Zhang, Y	1
Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y	1
Chirgwin, JM; Suvannasankha, A	1
Baloglu, E; Cao, Q; Chu, P; Doan, N; Forscher, C; Gery, S; Guo, X; Koeffler, HP; Lee, VK; Lim, HJ; Lin, DC; Marijon, H; Mayakonda, A; Pang, B; Rajalingam, R; Said, JW; Shacham, S; Sun, H; Thomas, T; Xu, L; Yang, H; Zhao, Z	1
Bouvet, M; Chishima, T; DeLong, JC; Dry, SM; Eckardt, MA; Eilber, FC; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; James, AW; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Russell, T; Singh, AS; Tanaka, K; Yanagawa, J; Zhang, Y	1
Amin, HM; Benjamin, RS; Buford, AS; Daw, NC; Fokt, I; Lamhamedi-Cherradi, SE; Lazar, AJ; Ludwig, JA; Maywald, RL; Menegaz, BA; Mikos, AG; Naing, A; Priebe, W; Ramamoorthy, V; Ratan, R; Rohren, EM; Skora, S; Subbiah, V; Vishwamitra, D; Wang, J; Wang, Y	1
Massey, AJ	1
Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L	1
Agyin, JK; Nair, HB; Roy, SS; Santhamma, B; Tekmal, RR	1
Cavero, S; Español, I; Funes, C; García, MC; Ibáñez, J; Iturbe, T; López, MD; Martínez, A; Tejedor, A	1
Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C	1
Berglund, J	1
Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS	1
Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK	1
Jung, W; Schroers, R; Zettl, F	1
Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J	1
Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG	1
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH	1
Capalbo, S; Chiefa, A; Delia, M; Diomede, D; Liso, V	1
Chaudhary, PM; Lu, G; Punj, V	1

Reviews

1 review(s) available for pyrazines and Bone Cancer

Article	Year
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast cancer research : BCR, 2014, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta	2014

Article

Year

Role of bone-anabolic agents in the treatment of breast cancer bone metastases.

Breast cancer research : BCR, 2014, Volume: 16, Issue:6

Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta

2014

Trials

3 trial(s) available for pyrazines and Bone Cancer

Article	Year
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Molecular oncology, 2014, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Purines; Pyrazines; Sarcoma, Ewing; Xenograft Model Antitumor Assays	2014
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome	2005
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome	2006

Other Studies

24 other study(ies) available for pyrazines and Bone Cancer

Article	Year
Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs. Toxicological sciences : an official journal of the Society of Toxicology, 2020, 01-01, Volume: 173, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cisplatin; Doxorubicin; Humans; Imidazoles; Osteoblasts; Pyrazines; Sarcoma, Ewing; Tissue Engineering; Tumor Microenvironment; Vincristine	2020
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells. Journal of radiation research, 2021, Sep-13, Volume: 62, Issue:5 Topics: Ataxia Telangiectasia Mutated Proteins; B7-H1 Antigen; Bone Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Heavy Ion Radiotherapy; Humans; Imaging, Three-Dimensional; Interferon Regulatory Factor-1; Linear Energy Transfer; Morpholines; Neoplasm Proteins; Osteosarcoma; Phosphorylation; Protein Processing, Post-Translational; Pyrazines; Pyrones; RNA, Messenger; RNA, Neoplasm; STAT1 Transcription Factor; Sulfones; Up-Regulation; X-Rays	2021
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Topics: Amides; Antiviral Agents; Bone Neoplasms; Chemical and Drug Induced Liver Injury; COVID-19; Humans; Methotrexate; Osteosarcoma; Pharmaceutical Preparations; Pyrazines; RNA, Viral; SARS-CoV-2	2022
The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer biology & therapy, 2017, Nov-02, Volume: 18, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Osteosarcoma; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin	2017
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC cancer, 2013, May-20, Volume: 13 Topics: Blotting, Western; Bone Neoplasms; Cell Proliferation; Humans; Imidazoles; Mesenchymal Stem Cells; Neoplasm Grading; Oligonucleotide Array Sequence Analysis; Osteoblasts; Osteosarcoma; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction	2013
Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo. Molecular medicine reports, 2013, Volume: 8, Issue:4 Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin D1; Down-Regulation; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA; Tumor Burden; Xenograft Model Antitumor Assays	2013
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome	2014
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-15, Volume: 111, Issue:28 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Delivery Systems; Heterografts; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Tumor Microenvironment; Xenograft Model Antitumor Assays	2014
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2. International journal of oncology, 2014, Volume: 45, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Ubiquitin-Protein Ligases	2014
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling. Cancer research, 2016, 05-01, Volume: 76, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Exportin 1 Protein; Female; Gene Knockdown Techniques; Humans; Hydrazines; Imidazoles; Immunoblotting; Immunohistochemistry; Insulin-Like Growth Factor I; Karyopherins; Mice; Mice, Nude; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Pyrazines; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA-Binding Protein EWS; Sarcoma, Ewing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays	2016
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget, 2016, Jul-26, Volume: 7, Issue:30 Topics: Animals; Bone Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Piperazines; Pyrazines; Pyridines; Receptor, IGF Type 1; RNA-Binding Protein FUS; Sarcoma, Ewing; Xenograft Model Antitumor Assays	2016
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:12 Topics: Adenosine Triphosphatases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Array Analysis; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma, Ewing; Sirolimus; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation	2016
Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy. Cancer letters, 2016, 12-01, Volume: 383, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; Cell Proliferation; Checkpoint Kinase 1; Colorectal Neoplasms; DNA Damage; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Histones; HT29 Cells; Humans; Indoles; Isoxazoles; Molecular Targeted Therapy; Nuclear Proteins; Osteosarcoma; Protein Kinase Inhibitors; Pyrazines; Pyridones; Signal Transduction; Time Factors	2016
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone. Leukemia research, 2009, Volume: 33, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine	2009
BU-32: a novel proteasome inhibitor for breast cancer. Breast cancer research : BCR, 2009, Volume: 11, Issue:5 Topics: Animals; Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chymotrypsin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays	2009
First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone. Leukemia research, 2010, Volume: 34, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Plasmacytoma; Pyrazines; Spinal Cord Compression; Treatment Outcome	2010
Development of a brain metastatic canine prostate cancer cell line. The Prostate, 2011, Volume: 71, Issue:12 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous	2011
Orthopaedics: Structural support. Nature, 2011, Dec-14, Volume: 480, Issue:7377 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosphonates; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Kyphoplasty; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines	2011
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure	2012
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials, 2012, Volume: 33, Issue:29 Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines	2012
[Multiple myeloma -- therapy]. Deutsche medizinische Wochenschrift (1946), 2005, Feb-11, Volume: 130, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2005
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:4 Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays	2005
Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Skull; Tomography, X-Ray Computed; Treatment Outcome	2007
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer biology & therapy, 2008, Volume: 7, Issue:4 Topics: Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand	2008